Everolimus is a derivative of rapamycin (a 'rapalog') that potently inhibits the mTORC1 signaling pathway. This pathway is a central regulator of cellular growth, metabolism, and aging. By dampening mTOR activity, everolimus can induce autophagy (cellular cleaning) and reduce inflammation, processes thought to be fundamental to extending healthspan.
Verdict
A powerful but high-risk mTOR inhibitor for experimental anti-aging use.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$5000 - $15000
Protocol
- Experimental healthspan protocols often involve low, intermittent doses such as 2.5 mg to 5 mg once per week, mimicking rapamycin regimens.
Flags
- Increases risk of serious infections due to its immunosuppressive effects.
- Common side effects include mouth sores (stomatitis), rash, fatigue, and diarrhea.
- Can cause significant metabolic changes, including high blood sugar and high cholesterol/triglycerides.
- Risk of rare but serious non-infectious pneumonitis (lung inflammation).
- May impair fertility in both males and females.
- Interacts with many common medications through the CYP3A4 enzyme pathway.